Search
Filter Results
Displaying 471–480 of 800 for “retinitis clinical trial”
-
Sep 22, 2021
Initial programs will focus on treatments for rare pediatric blinding conditions. Company formed to advance the work of scientific cofounders Dr. Jean Bennett, Junwei Sun and Dr. Eric Pierce.
-
Oct 28, 2021
RD Fund Announces Fundraising Efforts Underway for RD Fund 2
Patient-centric venture philanthropy model continues to invest in companies developing therapies for individuals affected by retinal degenerative diseases.
-
Oct 4, 2021
RD Fund Appoints Tony Adamis, MD to Board of Directors
The RD Fund announces the appointment of Anthony (Tony) Adamis, MD, to its board of directors.
-
Mar 5, 2020
ARVO 2014: LCA Gene Therapy Recipient Featured During Keynote
15-year-old Yannick Duwe transfixed the audience, describing how the treatment enabled him to use a computer instead of Braille, and work much easier and faster at school.
-
Feb 28, 2023
RD Fund Appoints Mark S. Blumenkranz, MD, MMS to Board of Directors
Ophthalmology visionary Mark S. Blumenkranz, MD, MMS, to join RD Fund’s Board.
-
Apr 27, 2021
Foundation Fighting Blindness Appoints Claire M. Gelfman, Ph.D. as Chief Scientific Officer
Dr. Gelfman brings over twenty years of successful ophthalmic research and development experience to the Foundation executive team.
-
Feb 3, 2020
7th Annual Retinal Cell and Gene Therapy Innovation Summit
Please note that the seventh annual Retinal Cell and Gene Therapy Innovation Summit previously scheduled for Friday, May 1st, 2020 in Baltimore, Maryland has been cancelled.
-
Jul 11, 2019
Gene Therapy Trials for Wet Age-Related Macular Degeneration
After a series of failed trials, current research suggests that the next generation of gene therapies for wet age-related macular degeneration holds promise. Learn how investigators are inducing the body’s cells to administer their own therapeutic response to disease activity.
-
Dec 15, 2023
Eye on the Cure Podcast | Episode 58: Jason Comander
Jason Comander, Md, PhD, clinical researcher, surgeon, and director of the Inherited Retinal Disease Disorders Service at Mass Eye and Ear, talks to host Ben Shaberman about his administration of LUXTURNA gene therapy to RPE65 patients, his team’s re-analysis of vitamin A therapy for retinitis pigmentosa, and passion for retinal research and patient care.